AngeCool to enter full clinical trial:
This article was originally published in Clinica
Executive Summary
Angeion has completed initial US trials in 20 patients of its AngeCool radiofrequency catheter ablation system for the treatment of supraventricular and atrial arrhythmias. The company will seek FDA permission to expand the trials of the product, which features a porous catheter tip to minimise blood coagulation. Other ablation technologies under development by Angeion include a linear RF ablation catheter for treating atrial fibrillation and two laser ablation products for the treatment of ventricular tachycardias.